TR201010618A2 - İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi - Google Patents

İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi

Info

Publication number
TR201010618A2
TR201010618A2 TR2010/10618A TR201010618A TR201010618A2 TR 201010618 A2 TR201010618 A2 TR 201010618A2 TR 2010/10618 A TR2010/10618 A TR 2010/10618A TR 201010618 A TR201010618 A TR 201010618A TR 201010618 A2 TR201010618 A2 TR 201010618A2
Authority
TR
Turkey
Prior art keywords
dosage form
oral dosage
imatinib
manufacture
syndrome
Prior art date
Application number
TR2010/10618A
Other languages
English (en)
Inventor
Bi̇lgi̇ç Mahmut
Original Assignee
Bi̇lgi̇ç Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bi̇lgi̇ç Mahmut filed Critical Bi̇lgi̇ç Mahmut
Priority to TR2010/10618A priority Critical patent/TR201010618A2/tr
Priority to PCT/TR2011/000274 priority patent/WO2012087255A2/en
Priority to PCT/TR2011/000275 priority patent/WO2012087256A2/en
Priority to PCT/TR2011/000276 priority patent/WO2012087257A2/en
Publication of TR201010618A2 publication Critical patent/TR201010618A2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Abstract

Akut lenfositik lösemi, gastrointestinal stromal tümörler (GIST), hipereozinofilik sendrom, kronik miyelojen lösemi (KML), miyelodisplastik sendrom ve sistemik mestositoz hastalıklarının tedavisinde kullanılmak üzere aktif madde olarak imatinib mesilat ? kristalini içeren oral dozaj formu ve bu oral dozaj formunun üretimi ile ilgilidir.
TR2010/10618A 2010-12-20 2010-12-20 İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi TR201010618A2 (tr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
TR2010/10618A TR201010618A2 (tr) 2010-12-20 2010-12-20 İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi
PCT/TR2011/000274 WO2012087255A2 (en) 2010-12-20 2011-12-19 Pharmaceutical formulations
PCT/TR2011/000275 WO2012087256A2 (en) 2010-12-20 2011-12-19 Pharmaceutical capsule formulations
PCT/TR2011/000276 WO2012087257A2 (en) 2010-12-20 2011-12-19 Oral dosage form comprising imatinib and production of said oral dosage form

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2010/10618A TR201010618A2 (tr) 2010-12-20 2010-12-20 İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi

Publications (1)

Publication Number Publication Date
TR201010618A2 true TR201010618A2 (tr) 2012-07-23

Family

ID=45529174

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2010/10618A TR201010618A2 (tr) 2010-12-20 2010-12-20 İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi

Country Status (2)

Country Link
TR (1) TR201010618A2 (tr)
WO (3) WO2012087256A2 (tr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL394169A1 (pl) * 2011-03-09 2012-09-10 Adamed Spółka Z Ograniczoną Odpowiedzialnością Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania
KR20140065862A (ko) * 2012-11-22 2014-05-30 에스케이케미칼주식회사 발포성 속붕해성 이매티닙 제제
GB201304699D0 (en) * 2013-03-15 2013-05-01 Remedica Ltd Pharmaceutical compositions
ES2683361T3 (es) * 2013-05-14 2018-09-26 Hetero Research Foundation Composiciones de Imatinib
US20160143850A1 (en) * 2013-07-09 2016-05-26 Shilpa Medicare Limited Oral Pharmaceutical Compositions Comprising Imatinib Mesylate
TWI608849B (zh) * 2014-06-16 2017-12-21 國邑藥品科技股份有限公司 可調控釋放度之高載藥量之醫藥組合物及其製備方法
EP3257499A1 (en) 2016-06-17 2017-12-20 Vipharm S.A. Process for preparation of imatinib methanesulfonate capsules
WO2019229648A1 (en) * 2018-05-28 2019-12-05 Shivalik Rasayan Limited Oral compositions of imatinib mesylate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (tr) * 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
ITMI992711A1 (it) * 1999-12-27 2001-06-27 Novartis Ag Composti organici
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
GB2398565A (en) 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
ES2341996T3 (es) * 2005-06-03 2010-06-30 Elan Pharma International Limited Formulaciones de mesilato de imatinib en forma de manoparticulas.
ATE445392T1 (de) * 2005-08-15 2009-10-15 Siegfried Generics Int Ag Filmtablette oder granulat enthaltend ein pyridylpyrimidin
US20060223817A1 (en) 2006-05-15 2006-10-05 Chemagis Ltd. Crystalline imatinib base and production process therefor
CA2662265A1 (en) * 2006-09-01 2008-03-06 Teva Pharmaceutical Industries Ltd. Imatinib compositions
BRPI0817946A2 (pt) * 2007-09-25 2015-05-05 Teva Pharma Composições de imatinibe estável

Also Published As

Publication number Publication date
WO2012087257A2 (en) 2012-06-28
WO2012087255A3 (en) 2012-08-16
WO2012087257A3 (en) 2012-09-27
WO2012087256A2 (en) 2012-06-28
WO2012087255A2 (en) 2012-06-28
WO2012087256A3 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
TR201010618A2 (tr) İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi
CY1123476T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CL2015000711A1 (es) Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona como inhibidores de notch; composicion farmaceutica y uso en el tratamiento del cancer.
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
CO6680717A2 (es) Derivados de quinolina y quinoxalina como inhibidores de cinasa
DK3061454T3 (da) Parasitiske orale veterinærsammensætninger omfattende systemisk-virkende aktivstoffer, fremgangsmåder og anvendelser deraf
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
CY1119798T1 (el) Μορφη iv υδροχλωρικης ιβαμπραδινης
NZ600887A (en) Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one lactic acid salts
CL2008002097A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de cinasa de fosfatidil-inositol-3; composicion farmaceutica; y uso en el tratamiento del cancer.
TR201819653T4 (tr) Karaciğer kanserinin tedavisinde kullanılmaya yönelik organik bileşik.
CL2012003340A1 (es) Composicion farmaceutica de administracion oral de bendamustina y su uso en el tratamiento oral de una condicion medica seleccionada de leucemia linfocitica cronica, cancer de mama, entre otras.
CY1119619T1 (el) Παραγωγα πυριδιν-4-υλιου
CL2015002897A1 (es) Inhibidores de bace1
PH12015501088A1 (en) Dimeric compounds
JP2012123959A5 (tr)
MX2015000362A (es) Benzo(b)-azepin-2-onas antiproliferativas.
TR201906685T4 (tr) Kristalin macitentan içeren farmasötik bileşim.
MX2014014308A (es) Pirrolidino heterociclos.
PH12015500399A1 (en) Azaindolines
CL2014001323A1 (es) Compuestos derivados de 3-fenil-isoquinolin-1(2h)-ona, inhibidores de parp-1; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer.
MX2015012386A (es) Inhibidores de la cinasa cdk9.
UY34154A (es) Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel.
MX2015012153A (es) Inhibidores de la quinasa pirrolopirimidina cdk9.